EC secures 80M doses of Moderna COVID-19 vaccine

By The Science Advisory Board staff writers

November 25, 2020 -- Moderna has announced that the European Commission (EC) has agreed to secure 80 million doses of its COVID-19 vaccine messenger RNA (mRNA)-1273.

The commission has the option to increase its purchase to up to 160 million doses. The agreement will be finalized after the European Union member states review it. Delivery of the doses could begin as early as the first quarter 2021 if the vaccine is approved by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), which began a rolling review of mRNA-1273 on November 17.

On November 16, it was announced that Moderna's vaccine had a 94.5% efficacy in a phase III clinical trial.

Moderna reports EMA review of COVID-19 vaccine candidate, U.K. supply deal
Moderna said that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use has initiated a rolling review of the firm's messenger...
Moderna reports 94.5% efficacy for COVID-19 vaccine
A COVID-19 vaccine under development by Moderna had 94.5% efficacy in a phase III clinical trial, according to an independent data safety monitoring board...
Moderna finalizes interim results for COVID-19 vaccine
Moderna has completed case accrual for its first interim analysis of a phase III study of its COVID-19 vaccine candidate.
If successful, COVID-19 vaccines could be worth $27B
Vaccines are considered one of the most effective public health measures preventing diseases in the modern world. They could also be very profitable endeavors,...
Takeda expands COVID-19 vaccine supply with Moderna, Japan
Takeda Pharmaceutical will import and distribute 50 million doses of messenger RNA (mRNA)-1273, Moderna's COVID-19 vaccine candidate, starting in...

Copyright © 2020 scienceboard.net


Conferences
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter